依赖葡萄糖的胰岛素型多涉及腹腔血液供应的食后调节
Rasmus S Rasmussen1, Ludvig S Langberg1, Frederikke Østergaard1
1Faculty of Health and Medical Sciences, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Diabetes
|May 30, 2025
概括
葡萄糖依赖的胰岛素型多 (GIP) 刺激了的血液流动. 阻断GIP受体减少了22%的食后肠道高血压,揭示了GIP在营养吸收和血流调节中的作用.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 血管生物学 血管生物学
背景情况:
- 胃肠道激素调节营养处理和葡萄糖代谢.
- 胃肠道激素可能会影响食后血流再分配.
- 葡萄糖依赖性胰岛素特异性多 (GIP) 在脊柱血流中的作用尚未完全理解.
研究的目的:
- 为了研究内源性依赖葡萄糖的胰岛素型多 (GIP) 在调节腹腔血流中的作用.
- 量化GIP对食后肠道高血压的贡献.
主要方法:
- 在10名健康男性中进行随机交叉研究.
- 在口服葡萄糖摄入期间输注GIP受体抗剂 (GIPR-An).
- 使用相对照MRI评估状血流. 用相对照MRI评估.
- 血激素和骨代谢标志物的测量.
主要成果:
- 在禁食状态下,GIP的使用刺激了上层中枢动脉的血流量~10%.
- 口服葡萄糖增加了~70%的上层中枢动脉血流和~40%的门静脉流量.
- 在口服葡萄糖期间输注GIPR-An可将上层中枢动脉血流的增加降低约22%,并降低胰岛素分泌.
结论:
- 内源性GIP显著增加了脊柱血流.
- 在健康的男性中,GIP有助于食后肠道高血压.
- GIP受体对抗剂可能会影响沟血流和荷尔蒙反应.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
Glucose Homeostasis: Regulation of Blood Glucose
2.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.6K
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


